A Pilot Study for Optimizing Meropenem Administration in the ICU

ConditionDrug Effect
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorOslo University Hospital

About this trial

Can antibiotic drugs be administered faster and make acceptable serum concentrations if we give short but multiple infusions compared to long and fewer infusions? In this study we will compare giving meropenem 1 gram 6 times daily in 15 minutes infusions to the recommended 2 gram 3 times daily in 3 hours infusions. In patients in the intensive care unit, the need for intravenous access is of essence. If 6 short infusions results in the same serum concentrations as 3 long infusions, we will increase intravenous access from 15 to 22.5 hours daily.

Eligibility criteria

Qualifiers

Patients ≥ 18 years admitted to the ICU at Oslo University Hospital, Rikshospitalet and

who shall be treated with meropenem because of proven or suspected serious infection and

who give their written informed consent either directly or through next of kin

Disqualifiers

with known hypersensistivity to betalactam antibiotics or

who use of valproat or

who are pregnant or

the lack of consent.

Trial design

Treatments tested in this trial

  • Meropenem 1000 mg

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators